UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~January 158, ~~2020~~2021

BIOPLUS LIFE CORP.

(Exact name of registrant as specified in its charter)

Nevada		~~333~~30-~~226885~~0987011		~~30-0987011~~
(State or other jurisdiction of incorporation)		(~~Commission~~IRS ~~File~~Employer ~~Number~~Identification No.)		~~(IRS Employer Identification No.)~~

No . 9 & 10 Jalan P4/8B< Bandar Teknologi Kajang

~~Jalan P4/8B~~Semenyih, Selangor D.E., Malaysia 43500

Bangar Teknologi Kajang

Semenyih , Selangor, Malaysia 43500

(Address of Principal Executive Offices)

+603 8703 2020

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

~~Indicate by~~Title ~~check mark whether the registrant is an emerging growth company as defined in Rule 405~~ of ~~the~~each ~~Securities~~class ~~Act~~Trading ~~of 1933~~ Symbol(~~§230.405 of this chapter~~s) orName ~~Rule 12b-2~~ of ~~the~~each ~~Securities~~exchange ~~Exchange~~on ~~Act~~which ofregistered ~~1934~~NA ~~(§240.12b-2~~NA ~~of this chapter).~~NA

~~Emerging growth~~Item ~~company~~4.01 ~~[ ]~~Change in Registrant’s Certifying Accountant

IfOn anJanuary ~~emerging~~8, ~~growth company~~2021, ~~indicate~~Bioplus byLife ~~check~~Corporation ~~mark if~~ (the ~~registrant~~Company) ~~has~~changed ~~elected~~its ~~not~~principal toaccountant ~~use~~from ~~the~~Total ~~extended~~Asia ~~transition~~Associates ~~period~~PLT ~~for~~(Total ~~complying~~Asia) ~~with~~to ~~any~~JP ~~new~~Centurion or& ~~revised~~Partners ~~financial~~PLT ~~accounting standards provided pursuant to Section 13~~(a)JP ~~of the Exchange Act~~Centurion). ~~[ ]~~

~~Item~~For 10K ended December 31, 2020 , the audit will be carried out by JP Centurion and it will also undertake the 10Q reviews of the Company for 2021. Accordingly, effective January 8, 2021, Total Asia resigned as the Company’s independent registered public accounting firm and JP Centurion became the Company’s independent registered public accounting firm.01 ~~Other~~This ~~Events~~change in the Company’s independent registered public accounting firm was approved by the Company’s Board of Directors on January 8, 2021.

OnThe ~~March~~principal 4,accountant’s ~~2020,~~reports ~~the~~of ~~U.S.~~Total ~~Securities~~Asia ~~and~~on ~~Exchange Commission (~~the ~~“SEC”)~~financial ~~issued~~statements ~~an order under Section 36 (Release No. 34-88318)~~ of the ~~Securities~~Company ~~Exchange Act of 1934,~~ as ~~amended (“Exchange Act”), granting exemptions from specified provisions~~ of ~~the Exchange Act~~ and ~~certain~~for ~~rules thereunder. On March 25, 2020,~~ the ~~order~~years ~~was~~ended ~~modified and superseded by a new~~December ~~SEC order (Release No. 34-88465)~~31, ~~which~~2019 provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and ~~any person~~2018 ~~required~~did tonot ~~make~~contain any ~~filings~~adverse ~~with~~opinion ~~respect to such registrant, is exempt from any requirement to file~~ or ~~furnish~~disclaimer ~~materials with~~of ~~the~~opinion ~~Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d)~~ and ~~Regulations~~were ~~13A,~~not ~~Regulation 13D-G~~qualified ~~(except for those provisions mandating the filing of Schedule 13D~~ or ~~amendments~~modified as to ~~Schedule 13D)~~uncertainty, ~~14A, 14C and 15D, and~~ ~~Exchange~~audit ~~Act~~scope ~~Rules~~or ~~13f-1,~~accounting ~~and 14f-1, as applicable, if certain conditions are satisfied~~principles.

~~COVID-19~~During isthe ~~currently~~fiscal ~~impacting~~years ~~countries,~~ended ~~communities,~~December ~~businesses~~31, 2019 and ~~markets~~2018, asand ~~well~~through asDecember ~~global~~31, ~~financial~~2020 , ~~markets.~~there ~~Although~~were ~~management cannot~~no ~~predict~~disagreements atwith ~~this~~Total Asia ~~time~~on ~~whether~~any ~~COVID-~~matter 9of ~~will~~accounting ~~have~~principles aor ~~material~~practices, ~~impact on our future~~ financial ~~condition~~statement ~~and results of operations~~disclosure, ~~our~~ ~~ability~~or toauditing ~~complete~~scope ~~and~~or ~~file~~procedure, ~~our Annual Report on Form 10-K for the fiscal year ended~~which ~~December~~if ~~31,~~not ~~2019~~resolved ~~(the~~to ~~“Report”)~~Total ~~has~~Asia’ ~~been~~satisfaction ~~impacted~~would ~~due~~have tocaused ~~government~~it ~~imposed restrictions related~~ to ~~the~~make ~~COVID-19 outbreak,~~reference ~~which~~thereto ~~have~~in ~~affected~~connection ~~our operations along~~ with ~~our~~its ~~accountants, auditors, consultants and professional~~reports ~~advisors~~on inthe ~~their~~financial ~~efforts~~statements tofor ~~timely~~such ~~file~~years. During the ~~Report.~~years Inended ~~reliance~~December on31, ~~the~~2018 ~~SEC~~and ~~Order~~2019, weand ~~will~~through ~~endeavor~~December to31, ~~file~~2020 , there ~~the~~were ~~Report~~ no ~~later~~reportable ~~than~~events ~~May~~of ~~14,~~the ~~2020,~~type ~~which~~described isin ~~within~~Item 45304(a)(1)(v) ~~days~~of ~~from~~Regulation ~~the original due date~~S-K.

~~Below~~During isthe afiscal ~~risk~~years ~~factor~~ended ~~regarding~~December ~~COVID-19~~31, ~~that~~2019 ~~our~~and ~~shareholders~~2018, and ~~potential~~through ~~investors~~December in31, us2020 , ~~should~~the ~~consider~~Company did not consult with JP Centurion with respect to any of (i) the ~~impact~~ application of accounting principles to a specified transaction, either completed or proposed; (ii) the ~~COVID-19~~type ~~pandemic~~of onaudit ~~our~~opinion ~~business~~that ~~operations~~might ~~and~~be ~~ability~~rendered toon ~~complete~~the Company’s financial statements; toor ~~comply~~(iii) ~~with~~any ~~our~~matter ~~reporting~~that was either ~~requirements~~the ~~under~~subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or an event of the ~~Exchange~~type ~~Act~~described in Item 304(a)(1)(v) of Regulation S-K.

AThe ~~pandemic~~Company provided JP Centurion , ~~epidemic~~with ora ~~outbreak~~copy of anthe ~~infectious~~foregoing ~~disease~~disclosure inand requested JP Centurion & Partners PLT, to furnish the ~~markets~~Company inwith ~~which~~a weletter ~~operate~~addressed orto ~~that~~the ~~otherwise~~Securities ~~impacts~~and ~~our~~Exchange ~~facilities~~Commission stating whether it agrees with the statements ormade ~~advisors~~therein. ~~could~~A ~~adversely~~copy ~~impact~~of ~~our~~such ~~business~~letter, ~~and/or~~dated ~~our~~January ~~ability~~8, to2021, ~~complete~~furnished ~~financial~~by ~~reports~~Total toAsia ~~enable~~Associates usPLT, tois ~~comply~~filed ~~with~~as ~~our~~Exhibit 16.1 to ~~reporting~~this ~~obligation~~Current ~~under~~Report ~~the~~on ~~Exchange~~Form ~~Act~~8-K.

If a pandemic, epidemic, or outbreak of an infectious disease including the recent outbreak of respiratory illness caused by a novel coronavirus (COVID-19) or other public health crisis were to affect our markets or facilities or those of our suppliers or accountants or advisors, our business could be adversely affected. A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our employees and professional advisors. These factors may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission.

Exhibit		Description

16.1		Letter to the Securities and Exchange Commission dated January 8, 2021 from Total Asia Associates PLT.

~~Cautionary Note Regarding Forward-Looking Statements~~2

This Current Report on Form 8-K contains statements that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events, including, without limitation, our future financial or business performance or strategies, results of operations or financial condition. These statements may be preceded by, followed by or include the words “may,” “might,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or similar expressions. These forward-looking statements are based on information available to us as of the date they were made and involve a number of risks and uncertainties which may cause them to turn out to be wrong. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, including the unprecedented impact of COVID-19 pandemic on our business, employees, consultants, service providers, shareholders, investors and other stakeholders, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Please refer to our Form 10-K to be filed with the SEC as well as any subsequent filings made by us pursuant to the Exchange Act, each of which is available on the SEC’s website (www.sec.gov), for a full discussion of the risks and other factors that may impact any forward-looking statements in this presentation.SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURE~~BIOPLUS LIFE CORP. /s/ Chong Khooi You Chong Khooi You President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

~~Pursuant to~~Date: ~~the~~February ~~requirements of the Securities Exchange Act of 1934~~9, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2021

BioPlus Life Corp.
(Registrant)
/s/ Chong Khooi You
Chong Khooi You		Dated:April 15, 2020
Chief Executive Officer (Principal Executive Officer)

Filing Compare · BIOPLUS LIFE CORP.